featured
Plasma cfDNA PIK3CA and TP53 Mutations Predicted Inferior Endocrine-Based Treatment Outcomes in Patients With ER+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Breast Cancer Res Treat 2023 Jun 21;[EPub Ahead of Print], TW Chen, W Hsiao, MS Dai, CH Lin, DY Chang, IC Chen, MY Wang, SH Chang, SM Huang, AL Cheng, KW Wu, KT Tan, YS LuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.